Markets:

Overview

News

Currencies

International

Treasuries

Sarepta Therapeutics, Inc. - Common Stock (NQ:SRPT)

17.67 -0.51 (-2.81%)

Delayed Quote Updated: 3:47 PM EDT, Oct 23, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Sarepta Therapeutics, Inc. - Common Stock

< Previous 1 2

...

26 27 28 29 30 31 32 33 34

...

36 37 Next >

Why Sarepta Therapeutics Stock Faded This Week ↗

May 11, 2023

The biotech's shares have turned volatile ahead of an important regulatory event.

Via The Motley Fool

FDA Staff Raises Issues For Sarepta's Duchenne Gene Therapy Data, Analyst Says Issues Known, Expects Positive Vote ↗

May 10, 2023

The FDA's Cellular, Tissue and Gene Therapies Advisory Committee is meeting this Friday to discuss Sarepta Therapeutics Inc's (NASDAQ: SRPT) to review SRP-9001 (delandistrogene moxeparvovec),...

Via Benzinga

Sarepta: The AdCom Documents Enter The Discussion ↗

May 10, 2023

The AdCom documents are going to stimulate a robust discussion about the upcoming vote.

Via Talk Markets

10 Health Care Stocks With Whale Alerts In Today's Session ↗

May 10, 2023

Via Benzinga

10 Health Care Stocks With Whale Alerts In Today's Session ↗

May 09, 2023

Via Benzinga

Expert Ratings for Sarepta Therapeutics ↗

May 03, 2023

Via Benzinga

Sarepta Therapeutics Earnings Preview ↗

May 01, 2023

Via Benzinga

Sarepta: More Drama Or Just More Noise? ↗

April 14, 2023

Sarepta has a history at the FDA and recent reports indicate additional issues. What are the implications for accelerated approval and the long term prospects of Sarepta?

Via Talk Markets

The Latest Analyst Ratings for Sarepta Therapeutics ↗

April 14, 2023

Via Benzinga

Market Rally Finishes Strong; Regional Banks, Fed Rate Hike, Jobs Report, Apple In Focus: Weekly Review ↗

May 05, 2023

The major indexes retreated for most of the week on banking fears,

Via Investor's Business Daily

Sarepta Therapeutics (SRPT) Q1 2023 Earnings Call Transcript ↗

May 03, 2023

SRPT earnings call for the period ending March 31, 2023.

Via The Motley Fool

Sarepta Therapeutics Announces First Quarter 2023 Financial Results and Recent Corporate Developments

May 02, 2023

From Sarepta Therapeutics, Inc.

Via Business Wire

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

April 28, 2023

From Sarepta Therapeutics, Inc.

Via Business Wire

Sarepta Therapeutics to Announce First Quarter 2023 Financial Results

April 25, 2023

From Sarepta Therapeutics, Inc.

Via Business Wire

This Biotech's Stock Has Been Under Pressure, Could Upcoming Clinical Trials Of Its Nanotechnology-Based COVID Drug Candidate Be The Start Of An Upward March? ↗

April 19, 2023

A company that seems to have seen poor market sentiment lately is NanoViricides Inc. (NYSEAMERICAN: NNVC), a pharmaceutical company specializing in the development of nanomedicine drugs for treating...

Via Benzinga

Bragar Eagel & Squire, P.C. Is Investigating Fox, Charles River, Provident, and Sarepta and Encourages Investors to Contact the Firm

April 17, 2023

From Bragar Eagel & Squire

Via GlobeNewswire

Analysts Says Stat News Article Adds Uncertainty To Sarepta's SRP-9001, But Offers Buying Opportunity Around The Weakness ↗

April 13, 2023

Via Benzinga

FDA Staff Had Inclination Towards Rejecting Sarepta Duchenne Gene Therapy ↗

April 13, 2023

Reviewers at the FDA were leaning toward rejecting Sarepta Therapeutics Inc's (NASDAQ: SRPT) closely watched gene therapy for Duchenne muscular dystrophy.

Via Benzinga

Sarepta Tumbles As Report Of Internal FDA Strife Scorches Its Gene Therapy ↗

April 13, 2023

According to a report, some staffers wanted to reject the highly watched drug.

Via Investor's Business Daily

Why Is Merck (MRK) Stock Up Today? ↗

April 13, 2023

Merck (MRK) stock is on the move Thursday after the pharmaceutical company got an update from the FDA concerning Keytruda.

Via InvestorPlace

Why Is BigBear.ai (BBAI) Stock Down 5% Today? ↗

April 13, 2023

BigBear.ai (BBAI) stock is taking a beating on Thursday after the AI company announced the details of a public stock offering.

Via InvestorPlace

Why Is Sarepta Therapeutics (SRPT) Stock Down 12% Today? ↗

April 13, 2023

Sarepta Therapeutics (SRPT) stock is taking a beating on Thursday following reports that the FDA was considering rejecting one of its drugs.

Via InvestorPlace

Why Sarepta Therapeutics Stock Is Tumbling Today ↗

April 13, 2023

Sarepta Therapeutics Inc (NASDAQ: SRPT) shares are trading lower Thursday on the heels of a report suggesting some U.S. Food and Drug Administration staff had opposition towards Sarepta gene therapy...

Via Benzinga

12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗

April 13, 2023

Via Benzinga

ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Sarepta Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation - SRPT

April 10, 2023

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

Via NewMediaWire

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Shareholder Notice: Investigation over Potential Securities Laws Violations ↗

April 10, 2023

San Diego, CA -- (SBWIRE) -- 04/10/2023 -- Sarepta Therapeutics, Inc. is under investigation over potential securities laws violations in connection with certain financial statements.

Via SBWire

Sarepta Therapeutics Announces that the Date of the Advisory Committee Meeting for SRP-9001 will be May 12, 2023

April 10, 2023

From Sarepta Therapeutics, Inc.

Via Business Wire

ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Sarepta Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation – SRPT

April 09, 2023

From The Rosen Law Firm PA

Via GlobeNewswire

2 Top Growth Stocks That Could Soar This Spring ↗

April 06, 2023

Exciting news on the way for both of these companies could send their stock prices screaming higher.

Via The Motley Fool

Benzinga's Top Ratings Upgrades, Downgrades For April 4, 2023 ↗

April 04, 2023

Via Benzinga

< Previous 1 2

...

26 27 28 29 30 31 32 33 34

...

36 37 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.